Anti-vegf Resistance

VEGF blockade can reduce vascular support and create tissue hypoxia, a low-oxygen condition. In response, tumors or diseased tissues may activate alternative proangiogenic signals that sustain blood-vessel formation despite continued treatment. This mechanism helps explain why an initially effective therapy may lose durability and why researchers examine hypoxia-linked signaling when interpreting an incomplete or declining response.

Supportive stromal cells and myeloid cells can be recruited or activated when VEGF signaling is blocked, providing an alternative environment that promotes vascular persistence. Increased pericyte coverage may also stabilize blood vessels and make them less dependent on VEGF-driven support. Together, these changes can preserve diseased tissue or tumor vasculature and contribute to treatment resistance.

Vessel co-option allows tumors or diseased tissues to use existing blood vessels rather than relying entirely on newly formed vessels driven by VEGF. Because this strategy does not depend on the same angiogenic route, VEGF blockade may have less effect when it predominates. Recognizing vessel co-option broadens interpretation of treatment failure beyond the simple loss of drug activity.

Resistance present from treatment onset suggests that the disease was not sufficiently dependent on VEGF signaling or already possessed bypass mechanisms. Resistance emerging after an initial response indicates that treatment-related adaptation may have developed over time, such as alternative proangiogenic signaling, cellular recruitment, vessel stabilization, or vessel co-option. Distinguishing these patterns supports more precise interpretation of response durability.

Researchers can begin by recognizing limited or lost treatment response and then examining which resistance mechanisms could explain it. The overview identifies biomarker discovery as a key next step, because biomarkers may indicate alternative proangiogenic signaling, supportive cell recruitment, pericyte coverage, or vessel co-option. This framework applies across oncology and retinal medicine while accounting for disease-specific biology.

Combination and sequential therapies are studied to address mechanisms that emerge alongside or instead of VEGF signaling. A combination approach may target more than one relevant pathway or cellular contribution, whereas sequential treatment changes the therapeutic strategy over time. The goal is to improve disease control, extend treatment durability, and guide more durable clinical responses.

Biomarkers can help researchers determine whether poor response reflects resistance from treatment onset or an adaptive process that developed after initial benefit. They may also provide clues about alternative proangiogenic signals, stromal or myeloid support, pericyte coverage, or vessel co-option. Such information can guide interpretation of treatment failure and inform the design of combination or sequential therapies.